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Background: As a known regulator of apoptosis, survivin has positive relationship with lymphatic metastasis in
breast cancer. This study aims to detect the difference in expression between survivin and vascular endothelial
growth factor-C (VEGF-C) in treated breast cancer cells and tissues, and to analyze the correlation among survivin,
VEGF-C and lymphatic metastasis.
Methods: Plasmid with survivin and VEGF-C shRNA and lentivirus with survivin gene were constructed and
transfected into breast cancer cell ZR-75-30. Then the expressions of the two genes were examined using western
blot analysis and real-time PCR. The change of invasiveness of breast cancer cells was assessed using matrigel
invasion assay. Using immunohistochemistry, the expression of survivin and VEGF-C were analyzed in 108 clinical
breast cancer cases with breast cancer tissue and lymph node.
Results: Survivin regulated the expression of VEGF-C at both protein and mRNA levels in breast cancer cells.
Immunohistochemical analysis showed that the level of VEGF-C expression was significantly related with that of
survivin in breast cancer tissues (p<0.05). VEGF-C was found to participate in the process of breast cancer cells
invasion mediated by survivin. The co-expression of the two and the single expression of any one took significant
difference in positive lymph node (p<0.05).
Conclusions: Survivin takes an important part in regulating the expression of VEGF-C. VEGF-C could influence the
invasive ability mediated by survivin. The co-expression of survivin and VEGF-C is more statistically significant to
assess lymphatic metastasis in breast cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9193530897100952
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Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer death in females,
accounting for 23% (1.38 million) of the total new cancer
cases and 14% (458,400) of the total cancer deaths in
2008 worldwide [1]. More than half of breast cancers are
associated with axillary nodal involvement. Metastasis
and recurrence severely affect the quality and length
of lives of breast cancer patients. In the NCCN clinical* Correspondence: xyzheng@mail.cmu.edu.cn
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reproduction in any medium, provided the orpractice guidelines of breast cancer, lymphatic metastasis
is considered the main criteria for clinical prognosis and
target of systemic treatment. Axillary lymph node status
is the most important prognostic factor in breast cancer,
and prognosis declines with increasing number of tumor-
positive lymph nodes [2].
Lymphatic metastasis is one of the most important
pathways of breast cancer systemic metastasis, and is
closely related to prognosis and therapy plans for breast
cancer patients. Many pathways have been suggested to
be involved in the process of breast cancer lymphatic
metastasis. And some markers, such as EGFR [3] and
BCRP [4], could be detected as the predictable target
of breast cancer lymphatic metastasis. Some researches
have indicated that survivin and vascular endothelial. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lymphatic metastasis of breast cancer.
Survivin is one of the inhibitors of apoptosis protein
(IAP). It regulates two important cellular processes in-
cluding inhibition of cell apoptosis and promoting cell
proliferation [5]. High levels of survivin mediate resist-
ance of cancer cells to a series of anti-cancer drugs [6],
and it has been shown that up-regulation of survivin
confers resistance of cancer cells to radiotherapy [7,8].
Several researches in breast cancer, gastric cancer, oral
squamous cell carcinoma and colorectal cancer have
shown that the expression of survivin is significantly
related to lymphatic metastasis, and that survivin is
the prognostic marker for these cancers [9-13]. How-
ever, how survivin controls lymphatic metastasis remains
elusive.
VEGF-C, also called lymphatic vessel growth factor, is
a lymphatic endothelial cell-stimulating factor. VEGF-C
affects blood vessel and lymphatic vessel through vascu-
lar endothelial growth factor receptor-2 (VEGFR-2) and
vascular endothelial growth factor receptor-3 (VEGFR-3),
respectively, to improve tumor growth and metastasis
[14]. High levels of VEGF-C have been detected inside or
around tumors lymphatic vessels, by which lymphatic and
even distal metastasis are promoted [15]. High levels of
VEGF-C also lead to lymphatic vessel formation in lymph
nodes [16]. Many researches have also demonstrated that
VEGF-C is involved in lymphatic invasion in esophageal
cancer, breast cancer, non-small cell lung cancer, and colo-
rectal cancer [17-20].
It has been suggested that both survivin and VEGF-C
play important roles in tumor lymphatic metastasis;
however, studies on the relationship between the two are
scarce. In this study, we discuss the relationship between
survivin and VEGF-C in breast cancer and the pathway




A total of 108 breast cancer patients aged 32 to 63 with
a mean age of 48 were involved in this study. All
patients were examined and monitored from 2009-
2011 in the First Affiliated Hospital of China Medical
University in Shenyang, Liaoning province, China. Breast
cancer was diagnosed and classified into various stages
according to the International Union Against Cancer
(UICC) and the TNM classification system published
by the American Joint Committee on Cancer (AJCC).
Clinical information obtained from the records and
the histopathology reports included age, first diagno-
sis, tumor size and grade, oestrogen-receptor (ER)
and progesterone-receptor (PR) status, and lymph nodal
involvement.Cell culture
Human breast cancer cell line ZR-75-30 was preserved
from Cell Resoure Center of Shanghai Life Science Re-
search Institute, Chinese Academy of Sciences. And it
was cultured in RPM1640 medium (Invitrogen Corpor-
ation, Carlsbad, California, USA) supplemented with
50 μg/ml penicillin, 50 μg/ml streptomycin and 10% fetal
bovine serum at 37°C in a 5% CO2 environment. Long
phase cells were collected after trypsin digestion by cen-
trifugation for 5 minute at 1,000 rpm, re-suspended in
phosphate buffered saline (PBS), and counted using a
haemocytometer.
Construction and transfection of plasmid-ShRNA and
lentivirus
Plasmids with survivin-shRNA and VEGF-C-shRNA were
constructed by Shanghai GennePharma Co., Ltd, and
lentivirus with survivin gene was constructed by Shanghai
GeneChem Co., Ltd. Plasmid-survivin-shRNA and plas-
mid-VEGF-C-shRNA, 10 μg shRNA and 25 μl Lipofecta-
mine 2000 (Invitrogen Corporation, Carlsbad, California,
USA) were mixed in 1350 μl 1640 medium without FBS
and transfected into brest cancer cells. The mixture were
added into 25-cm2 culture flask that was previously
plated with 1 × 106 ZR-75-30 breast cancer cells. Culture
medium was replaced with complete 1640 medium once
six hours post inoculation and cells were collected after
another 28 hours. Protein and RNA were extracted for
western blot and real-time PCR analysis, respectively.
Lentivirus with survivin gene was transfected into cells
at an MOI of 20 and 0.75 μl polyprene were added into
each well of the 6-well plate containing 2 × 105 ZR-75-30
cells. Medium was replaced after 8 hours, and then cells
were cultured at 37°C in a 5% CO2 environment.
Western blot analysis
Proteins were separated by SDS-PAGE, transferred onto
nitrocellulose membranes, and detected using relevant
primary antibody and appropriate secondary antibody.
Primary antibodies included: anti-survivin (mouse mono-
clonal, Santa Cruz, CA, USA), anti-VEGF-C (rabbit poly-
clonal, ABGENT, San Diego, CA, USA) and anti-β-actin
(mouse monoclonal, Santa Cruz, CA, USA).
RNA isolation and Real-time polymerase chain reaction
Total RNA was extracted using the guanidinium
thiocyanate-phenol-chloroform method. RNA yield and
purity were determined photometrically (BioPhotometer,
Eppendorf, Germany). Reverse transcription was per-
formed. Survivin and VEGF-C were amplified using real
time PCR. A total of 10 ng of reverse-transcribed total
RNA was used as the template, and PCR reaction con-
tained 20 pmol/ml of each sense and antisense primer
(Table 1) and SYBR Premix Ex Taq II (TaKaRa, Dalian,
Table 1 Primers used for real-time PCR
Primer 50-30 sequence Size of
PCR (bp)
Survivin forward TCATAGAGCTGCAGGGTGGATTGT 114
reverse AGTAGGGTCCACAGCAGTGTTTGA
VEGF-C forward AACCTCCATGTGTGTCCGTC 156
reverse TGGCAAAACTGATTGTTACTGG
GAPDH forward ACAGTCCATGCCATCACTGCC 266
reverse GCCTGCTTCACCACCTTCTTG
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PRISM 7700 Sequence Detection System Instrument (Ap-
plied Biosystems) was used for the amplification. Cycling
conditions consisted of an initial denaturation step at 95°C
for 10 min as a ‘hot start’, followed by 40 cycles of 95°C for
15 s, annealing temperature for 30 s, 72°C for 30 s, and a
final extension at 72°C for 10 min. GAPDH was used
in each experiment as an endogenous control. RelativeFigure 1 Expression of survivin and VEGF-C in different processed cel
protein expression; c and d: real-time PCR for mRNA expresison. * means s
statistically significant increase comparing to 30 (both p<0.05). (30 = ZR-75-
lv-N = lentivirus with negative control; p-S = survivin shRNA; p-V = VEGF-C shquantification for a gene was expressed as fold changes
over the control group. Fold changes were calculated
using the 2- ΔΔCt method.
Matrigel invasion assay
The migration capacity of breast cancer cells was deter-
mined in vitro using Transwell Chambers (Corning,
NY, USA) in which the two chambers were separated
with matrigel coated polycarbonate membrane (6.5-mm
diameter inserts, 8 μm pore size). Breast cancer cells
(5 × 105/ml serum-free medium) were placed in the
upper chamber (200 μl). The lower chamber contained
medium alone (500 μl). Chambers were assembled and
kept in an incubator for 24 hours. At the desired time
point, cells from the upper surface of the membrane
were removed with gentle swabbing and the migrant
cells on the lower surface of the membrane were fixed
by methanol and stained with crystal violet. Then mem-
branes were washed with PBS and mounted onto slidels at protein and mRNA level. a and b: western blot analysis for
tatistically significant decrease comparing to 30, and ** means
30 breast cancer cell line; p-N= plasmid with negative control;
RNA; lv-S = lentivirus with survivin gene).
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(Olympus BX41) and cellular migration per sample was
determined by counting the number of stained cells in at
least four to five randomly selected fields. Data are pre-
sented as mean number of the migrating cells ± SD per
microscopic field per sample. Each cell migration experi-
ment was repeated at least three times.
Immunohistochemical analysis
Immunohistochemistry was carried out on paraffin-
embedded tumor specimens fixed in 4% buffered for-
malin. Four-micrometer-thick histological slides were
de-paraffinized in xylol and heated in 0.01 M citrate buffer
for 25 min in a microwave oven. After cooled for 20 min
and washed in PBS, endogenous peroxidase was detected
by incubating samples with PBS containing 10% normal
goat serum for 30 min. Then the sections were incubated
with each primary antibody overnight at 4°C. The primary
antibodies were anti-survivin (mouse monoclonal, Santa
Cruz, CA., USA, 1:10) and anti-VEGF-C (rabbit poly-
clonal, Abcam Inc, Cambridge, MA, UK, 1:200). A further
wash in PBS was followed by treatment with peroxidase-
labeled polymer conjugated to goat anti-mouse or anti-
rabbit immunogloblins (Envison+ kit; Dako, Glostrup,
Denmark) as the secondary antibody for 10 min at room
temperature. The staining was visualized with diamino-
benzidine (DAB), followed by counterstaining with
hematoxylin. For a negative control, PBS was substituted
for the primary antibody.Figure 2 Matrigel invasion assay from different processed cells. a,b,c an
and group 30+ lv-S + p-V under a microscope(200×). e shows the mean num
different between 30+ lv-S and ZR-75-30 cells. ** means significant different bThe degree of immunohistochemical staining was
recorded on a scale of 0–3 according to the percentages of
staining and distributions within the cytoplasm. Tumors
were scored on a four-tier system: less than 10% of cancer
cells staining was designated negative (as degree 0), 10–
20% positive staining was scored as degree 1+, 21–50%
positive staining was scored as degree 2+, and 51–100%
positive staining was scored as degree 3+. We checked at
least five 200× visual fields for one glass slide under
microscope, counted the percentage of positive cells in
every fields and got the mean percentage of positive cells
in a glass slide. At last, we got the score of the glass slide
on the base of percentage.
Statistical analysis
Data was expressed as the means of at least three differ-
ent experiments ± SD. The results were analyzed by chi-
square test and Spearman analysis. p<0.05 was considered
statistically significant.
Results
Transfection of plasmid and lentivirus
Plasmids with survivn shRNA and VEGF-C shRNA con-
tained green fluorescent protein (GFP) were transfected
into cells using the method mentioned above. The trans-
fection efficiency was about 50%–70% after 24 hours.
Lentivirus-survivin with GFP was transfected into cells
using the method mentioned above. The transfection ef-
ficiency was nearly 100%.d d show the invasive cells of group 30, group 30+ lv, group 30+ lv-S
ber counted from above visual field. * means statistically significant
etween 30+ lv-S and 30+ lv-S +p-V(both p<0.05).
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correlated
In ZR-75-30 cells, when survivin was down-regulated,
VEGF-C was down-regulated with western blot method.
When survivin was up-regulated, VEGF-C had a higher
expression level than that in normal cells. In ZR-75-30
cells over-expressing survivin, VEGF-C expression level
also decreased when survivin was down-regulated. Real-
time PCR showed that the level of VEGF-C mRNA
positively correlated with the level of survivin mRNA
(Figure 1).Survivin changed invasive ability of cells through VEGF-C
In the matrigel invasion assay, breast cancer cells with high
levels of survivin were more invasive than those with low
levels of survivin, which suggested that survivin played an
important role in tumor cells migration. However,
down-regulated VEGF-C in these cells significantly
reduced the number of breast cancer cells that could
migrate through the polycarbonate membrane (Figure 2).Figure 3 Results of immunohistochemical staining of breast cancer ti
degree 0-3+ in breast cancer tissue; b shows VEGF-C expression in the ord
expressions in negative and metastatic lymph node respectively(200×).Survivin and VEGF-C expression in tumor tissue and
lymph node
Survivin and VEGF-C mainly localized in the cytoplasm,
but could also be detected in the nuclei with nuclear-
specific dye. Survivin was expressed in the breast cancer
tissue of 83.3% of the patients, among which degree 1-3+
were expressed at 26.7%, 50.0%, 23.3%. In the same group
of patients, VEGF-C was expressed at 77.8% and degree 1-
3+ were 28.6%, 53.6%, 17.9%. In the lymph node tissue,
both survivin and VEGF-C were expressed at higher levels
in positive LN than in negative LN (Figure 3).Pathological analysis of patients
Survivin and VEGF-C were expressed at higher levels in
patients with lymphatic metastasis, and stage III, IV breast
cancers (Table 2). The expression levels were also statisti-
cally different in tumors of different sizes. However, there
were no differences in the expression of the two genes in
patients with different age, histological grade, pathological
style, or ER/PR status. The results showed that higherssue and lymph node. a shows survivin expression in the order of
er of degree 0-3+ in breast cancer tissue; c shows survivin and VEGF-C
Table 2 Association of survivin and VEGF-C protein expression with clinicopathological features in breast cancer
patients
Variable n Survivin- Survivin+ χ2 p VEGF-C - VEGF-C + χ2 p
Age 0 1 0.965 0.326
≤45 years 36 6 30 6 30
>45 years 72 12 60 18 54
Tumor size 9.305 0.01 4.102 0.129
T1 39 12 27 12 27
T2 60 6 54 9 51
T3 9 0 9 3 6
Histological grade 0.873 0.350 0.175 0.675
I + II 99 15 84 21 78
III 9 3 6 3 6
Pathological style 0.169 0.681 0 1
ISC 12 3 9 3 9
IC 96 15 81 21 75
Lymph node metastasis 16.283 0.000 18.544 0.000
Negative 30 12 18 15 15
Positive 78 6 72 9 69
C-erBb-2 8.269 0.004 4.354 0.037
positive(3 + ) 12 6 6 6 6
negative(0-2 + ) 96 12 84 18 78
ER 0.617 0.432 0.882 0.348
positive 63 9 54 12 51
negative 45 9 36 12 33
PR 0 1 1.929 0.165
positive 54 9 45 15 39
negative 54 9 45 9 45
TNM stage 10.800 0.001 6.027 0.014
I, II 72 18 54 21 51
III, IV 36 0 36 3 33
ISC, in situ carcinoma; IC, invasive carcinoma.
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C-erBb-2 negative patients.
There was significant difference between the levels of
VEGF-C and survivin expression (p<0.05) (Table 3).
When the level of survivin expression increased from
degree 0 to 3, the level of VEGF-C expression increased
correspondingly. And the Pearson coefficient of contingencyTable 3 Relationship of expression extent between
surivivin and VEGF-C
VEGF-C 0-1+ VEGF-C 2+ VEGF-C 3+ χ2 p
Survvin 0-1+ 30 9 3 38.769 0.000
Survivin 2+ 12 30 3
Survivin 3+ 6 6 9C=0.514, which means an actual expression relationship
between VEGF-C and survivin.
In the patients with co-expression of survivin and
VEGF-C, the lymph node positive rate is higher than the
patients with the single or none expression of survivin
and VEGF-C (p<0.05) (Table 4). This result indicated
that survivin co-operated with VEGF-C in lymphatic
metastasis.Table 4 Relationship of co-expression of survivin and
VEGF-C with lymph node involvement
Survivin(−/+)/VEGF-C(−/+) Survivin(+)&VEGF-C(+) χ2 p
LN- 12 18 4.985 0.026
LN+ 15 63
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The expression of survivin is high during fetal develop-
ment but low in healthy adult tissues. However, in most
malignant tumors, the expression of survivin increases.
As a result, survivin has been considered a potential
tumor marker and an important therapeutic target [5].
Studies show that the expression of survivin in many kinds
of tumors correlates with lymphatic metastasis. Our
results suggest that survivin may influence breast cancer
lymphatic metastasis and distal invasion through VEGF-C.
Researches on different tumors have indicated that the
up-regulation of VEGF-C promotes tumor lymphatic
vessel formation and increases lymph node metastasis.
VEGF-C could form lots of lymphatic vessel inside or
around the tumor, by which promoting tumor metastasis
to lymph node and even distal organs [15]. Then it
could make a good condition for advanced metastasis and
diffusion.
We showed that the protein and mRNA expression of
VEGF-C are controlled by survivin. So, there must be a
notal point by which the expression of VEGF-C could be
regulated by survivin. Cox-2 activation is highly corre-
lated with VEGF-C expression [21], and through its down-
stream molecules, cox-2 is able to up-regulate the
expression of VEGF-C in cancer cells [22,23]. As an
important regulator of apoptosis, cox-2 is usually over-
expressed with survivin in hepatocellular carcinoma, sur-
perficial urothelial carcinoma and endometrial carcinoma
[24-26]. It is possible that cox-2 may be the notal point to
link survivin and VEGF-C expressions.
It has been suggested that the interaction of XIAP
and survivin promotes the invasion of tumor cells and
enhances the metastatic spread in vivo [27]. Khan et al.
have shown that synthetic survivin enhances the prolifera-
tion, drug resistance, and cellular invasion of tumor cells
[28]. It has been suggested that VEGF-C could promote
the VEGFR3 positive tumor cells invade to lymphatic ves-
sels through autocrine and CCR-7 dependent paracrine
mechanism [29]. VEGF-C was also proven to control
tumor cells growth and invasion by atuocrine mechanism
in the carcinoma of gallbladder [30]. In accordance with
this result, our results show that the invasiveness of breast
cancer cell increases when survivin is over-expressed, and
significantly decreases when survivn is over-expressed
while VEGF-C is down-regulated. So VEGF-C may play an
important role in enhancing the invasiveness in tumor
cells caused by survivin. On the other hand, in positive
lymph node, survivin and VEGF-C both express at high
levels, which may indicate that both of them play import-
ant roles in lymphatic metastasis and invasion in breast
cancer.
Several researches found that survivin and VEGF-C
took high level expression in the breast cancer, also had
positive relationship with positive lymphatic metastasisrespectively [9,31,32]. And not only in the primary
breast tumor, survivin was also found high level expres-
sion in circulating tumor cells in peripheral blood
through RT-PCR ELISA method [33]. It suggested that
the tumor cells with survivin high expression showed
great invasive and metastatic ability. In our study, it has
been proven that survivin and VEGF-C both are closely
related with lymphatic metastasis in different tumors.
We show in our study that survivin and VEGF-C expres-
sion are positively correlated, and the co-expression of
the two is also positively correlated with positive lymph
node. This result supports the conclusion based on pre-
vious finding that changes in survivin expression induce
the changes in VEGF-C expression.
Conclusion
As a conclusion, survivin is related with breast cancer
lymphatic metastasis. It gets correlation with the rate of
lymph node metastasis and the invasive ability of breast
cancer cells. VEGF-C may play an important role in
these processes. Survivin can influenced the expression of
VEGF-C to reduce breast cancer lymphatic metastasis and
invasion, which helps to decrease death risk of breast
cancer. Meanwhile, survivin and VEGF-C can be used
simultaneously as important markers to access lymphatic
metastasis and distal invasion of breast cancer.
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